Edition:
India

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

61.24EUR
3:58pm IST
Change (% chg)

€1.64 (+2.75%)
Prev Close
€59.60
Open
€60.00
Day's High
€61.34
Day's Low
€59.97
Volume
1,104,545
Avg. Vol
3,616,361
52-wk High
€97.03
52-wk Low
€52.02

Summary

Name Age Since Current Position

Werner Wenning

72 2012 Independent Chairman of the Supervisory Board

Werner Baumann

56 2016 Chairman of the Management Board, Chief Executive Officer

Oliver Zuehlke

50 2015 Independent Vice Chairman of the Supervisory Board, Employee Representative

Wolfgang Nickl

49 2018 Chief Financial Officer, Member of the Management Board

Hartmut Klusik

62 2016 Member of the Management Board, Director of Human Resources, Technology & Sustainability, Labor Director

Liam Condon

51 2016 Member of the Management Board, Head of the Crop Science Division, Animal Health Business Unit

Kemal Malik

56 2014 Member of the Management Board, Innovation and the Latin America Region

Stefan Oelrich

50 2018 Member of the Management Board, Head of the Pharmaceuticals Division

Heiko Schipper

49 2018 Member of the Management Board, Head of the Consumer Health Division

Paul Achleitner

62 2002 Independent Member of the Supervisory Board

Simone Bagel-Trah

50 2014 Independent Member of the Supervisory Board

Norbert Bischofberger

63 2017 Independent Member of the Supervisory Board

Thomas Ebeling

60 2012 Independent Member of the Supervisory Board

Thomas Elsner

60 2017 Independent Member of the Supervisory Board, Employee Representative

Johanna Faber

49 2016 Independent Member of the Supervisory Board

Colleen Goggins

64 2017 Independent Member of the Supervisory Board

Heike Hausfeld

53 2017 Independent Member of the Supervisory Board, Employee Representative

Reiner Hoffmann

63 2006 Independent Member of the Supervisory Board, Employee Representative

Frank Loellgen

57 2015 Independent Member of the Supervisory Board, Employee Representative

Wolfgang Plischke

67 2016 Independent Member of the Supervisory Board

Petra Reinbold-Knape

59 2012 Independent Member of the Supervisory Board, Employee Representative

Detlef Rennings

53 2017 Independent Member of the Supervisory Board, Employee Representative

Sabine Schaab

52 2017 Independent Member of the Supervisory Board, Employee Representative

Michael Schmidt-Kiessling

59 2012 Independent Member of the Supervisory Board, Employee Representative

Andre van Broich

48 2012 Independent Member of the Supervisory Board, Employee Representative

Otmar Wiestler

62 2014 Independent Member of the Supervisory Board

Norbert Winkeljohann

61 2018 Independent Member of the Supervisory Board

Juergen Beunink

2017 Senior Manager, Investor Relations

Biographies

Name Description

Werner Wenning

Mr. Werner Wenning has been Independent Chairman of the Supervisory Board of Bayer Aktiengesellschaft since October 1, 2012. He is Chairman of the Presidial Committee/Mediation Committee, the Human Resources Committee and the Nominations Committee, and Member of the Audit Committee and Innovation Committee at the Company. He joined Bayer on April 1, 1966 as a commercial trainee. After completing his vocational training and a one-year program in finance and accounting, he worked for a year in Corporate Auditing before being sent to Lima, Peru, in 1970 to establish and head up the finance department at the newly founded Bayer Industrial S.A. When he returned to Germany, he spent a further three years in the Corporate Auditing department. In 1978, he went back to Lima as Managing Director and administrative head of the Peruvian company. In 1983, he was appointed head of the staff department of what was then the Health Care Sector in Leverkusen. Three years later he transferred to the Plastics Business Group as head of marketing for thermoplastics. In 1987 he assumed responsibility for this business group’s global marketing operations. Starting on April 1, 1991, he was seconded for a year to the “Treuhandanstalt,” the Berlin-based privatization agency that helped to rebuild the economy in eastern Germany following reunification. In 1992, he was appointed Managing Director of Bayer Hispania Industrial S.A., Barcelona, and Senior Bayer Representative for Spain. In April 1996 he returned to Leverkusen to become head of Corporate Planning and Controlling. He was appointed to the Bayer AG Board of Management as Chief Financial Officer in February 1997 and took over as its Chairman in April 2002. He has been on the Supervisory Board of Henkel Management AG and Siemens AG (Vice Chairman).

Werner Baumann

Mr. Werner Baumann has served as Chairman of the Management Board and Chief Executive Officer of Bayer Aktiengesellschaft since May 1, 2016. Previously he served as Member of the Management Board, Strategy and Portfolio Management, Europe/Middle East/Africa Region at Bayer AG from January 1, 2016 till April 30, 2016. After studying economics at RWTH Aachen Universitaet and the University of Cologne, he joined Bayer in 1988. His first duties were in the Corporate Finance Department in Leverkusen. In 1991 he transferred to Bayer Hispania Comercial in Barcelona, Spain, to take up a position as controller, becoming assistant to the managing director in 1995. A year later, Baumann moved to Bayer Corporation in Tarrytown, New York, latterly heading up the global Business Planning & Administration organization of the Diagnostics Business Group. In July 2002, Baumann returned to Germany to become a member of the Executive Committee and Head of Central Administration & Organization at Bayer HealthCare. In October 2003 he was appointed a member of the Board of Management of the newly formed subgroup Bayer HealthCare AG, also serving as the company's Labor Director. As a member of the Board of Management and Labor Director of Bayer Schering Pharma AG, Berlin, Germany, from 2006 through September 2009, he actively participated in this company's integration into the subgroup. Prior to October 1, 2014, he served as Bayer AG’s Chief Financial Officer (CFO).

Oliver Zuehlke

Mr. Oliver Zuehlke has been Independent Vice Chairman of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since July 2015. He was Member of the Supervisory Board and Employee Representative at the Company from April 27, 2007. He is Member of the Presidial Committee/Mediation Committee, the Audit Committee and the Innovation Committee at the Company. He joined Bayer AG in Leverkusen, Germany, in 1985 and trained as a chemical production technician. During his training, in 1988, he became a member of the body representing young employees and apprentices. He chaired this body from 1990 to 1994. He was elected a full-time member of the Works Council at the Leverkusen site in 1994 and was Deputy Chairman from 2002 to 2010. Since then, he has also been a member of the Economics Committee of Bayer AG. In 2009, he completed a distance learning course on human resources management. Between 2010 and 2015 he was Chairman of the Works Council at the Leverkusen site and also held various functions in the German Mining, Chemical and Power Workers' Union (IG BCE). He was a member of the District Executive, the Regional Executive, the federal industrial group for the chemical industry, and the advisory board. From 2009 to 2015 Zuehlke was Chairman of the Bayer European Forum. In 2014 he became Member of the Supervisory Board of Bayer Pharma AG. Since 2015 he has been Chairman of the Central Works Council of Bayer AG.

Wolfgang Nickl

Mr. Wolfgang U. Nickl has been Chief Financial Officer, Member of the Management Board of Bayer Aktiengesellschaft since June 1, 2018. He has been Member of the Management Board at the Company since April 26, 2018. He completed a Bachelor of Business Administration (BBA) at the University of Cooperative Education Stuttgart (Duale Hochschule Baden-Wuerttemberg) in 1992 and obtained a Master of Business Administration (MBA) from the Marshall School of Business at the University of Southern California in Los Angeles, United States, in 2005. Starting in 1992, he acquired his first professional experience as a consultant and controller for German IT service provider SerCon. In 1995, he joined Western Digital Corporation, San Jose, California, a manufacturer of hard disk drives and other data storage products. His first roles at this company were as Business Planning Manager in the Netherlands and then as Director Business Solutions in the United States. In 2000, Mr. Nickl was appointed Chief Financial Officer at IT company Converge in the United States. Two years later, he returned to Western Digital where he held a number of finance positions with increasing responsibility. He also headed World Business Operations at this company for a number of years before being promoted to Chief Financial Officer in 2010. In December 2013, Mr. Nickl joined ASML N.V. in the Netherlands as Executive Vice President and Chief Financial Officer.

Hartmut Klusik

Dr. Hartmut Klusik has served as Member of the Management Board, Director of Human Resources, Technology & Sustainability and Labor Director of Bayer Aktiengesellschaft since January 1, 2016. On completing his studies in chemistry and gaining his doctorate from Philipps-Universitaet Marburg, Germany, he began his professional career at Bayer’s Wolff Walsrode AG subsidiary in 1984 as a laboratory manager. He then worked as head of operations in various production areas at Wolff Walsrode. In 1990, he transferred to Bayer AG and was appointed head of the company’s crop protection production in Brazil. This was followed by assignments in the United States and Australia. In 1997, he took charge of crop protection active ingredient production in Dormagen and Elberfeld, assuming global responsibility for active ingredient production at Bayer CropScience in Monheim from 2002. In early 2005, he transferred to Bayer HealthCare as head of the Technical Operations Committee. He was appointed to the Bayer HealthCare Executive Committee in July 2005 and was responsible for Product Supply. From November 2005 until his appointment to the Board of Management of Bayer AG, Dr. Klusik was Member of the Board of Management of Bayer HealthCare AG and became Labor Director as of October 2009. From March 2011 he was also Labor Director and member of the Board of Management of Bayer Pharma AG.

Liam Condon

Mr. Liam Condon has served as Member of the Management Board, Head of the Crop Science Division and is responsible for the Animal Health Business Unit at Bayer Aktiengesellschaft since January 1, 2016. He studied international marketing and languages at Dublin City University and at Technische Universitaet Berlin (TU Berlin). After graduating, he joined the former Schering AG and held various sales and marketing positions in the gynecology business in Germany. He then served five years as head of a business unit in Osaka, Japan. On his return to Germany, he became Regional Marketing and Medical Director for the Asia-Pacific and Middle East regions at Schering in Berlin. In February 2005, he was appointed Managing Director of Schering in China. Following Bayer’s acquisition of Schering, he was named Vice President of Bayer HealthCare China in November 2006. Between 2007 and 2009, he was Managing Director of Bayer HealthCare and General Manager of Bayer Pharma in China. In January 2010, Mr. Condon was appointed Managing Director of Bayer HealthCare in Germany and country representative for Bayer Schering Pharma in Germany. In December 2012, he became Chairman of the Board of Management of Bayer CropScience AG. He is Member of the Board of Directors of CropLife International, an agricultural industry association.

Kemal Malik

Mr. Kemal Malik has served as Member of the Management Board for Innovation and the Latin America Region at Bayer Aktiengesellschaft since February 1, 2014. He studied medicine in London, graduating as a Bachelor of Medicine, Bachelor of Surgery (MBBS) in 1987. He subsequently spent several years in clinical medicine at the Northwick Park Clinical Research Centre and at Hammersmith Hospital, London. He then held various positions of increasing responsibility in medical affairs and clinical development at Bristol-Myers Squibb. He joined Bayer in 1995 as Head of Metabolism and Oncology Europe in the then Pharmaceuticals Business Group. He subsequently served as Head of Global Medical Development before being appointed Head of Global Development and a member of the Executive Committee of Bayer HealthCare AG until his appointment to the Board of Management of Bayer AG.

Stefan Oelrich

Mr. Stefan Oelrich has been Member of the Management Board, Head of the Pharmaceuticals Division of Bayer Aktiengesellschaft since November 1, 2018. After graduating from high school in Paris, France, he joined Bayer AG as a commercial trainee in 1989 and qualified as a commercial assistant in 1991. Over the next 20 years, he held a number of positions of increasing responsibility in the health care business in Latin America, Europe and the United States. In 1998, after working in Argentina and Uruguay, Mr. Oelrich transferred to headquarters in Leverkusen for two years before assuming responsibility for Pharmaceuticals in Belgium. Between 2003 and 2005, he was Vice President of Marketing at Pharmaceuticals in the United States. He was subsequently appointed President of Healthcare and Diagnostics in France. In 2006, Mr. Oelrich returned to the United States as Senior Vice President and General Manager of Women’s Healthcare. In 2011, he joined Sanofi as General Manager in Germany, Switzerland and Austria. In 2015, Mr. Oelrich became head of Sanofi’s Diabetes and Cardiovascular business unit in Europe. At the same time, he served as Sanofi Europe Coordinator. In 2016, Mr. Oelrich became head of Sanofi’s global diabetes franchise. A year later, he was appointed Executive Vice President Diabetes & Cardiovascular on the Executive Committee of Sanofi. Since 2016, Mr. Oelrich has been Member of the Supervisory Board of the Berlin Institute of Health.

Heiko Schipper

Mr. Heiko Schipper has been Member of the Management Board and Head of the Consumer Health Division at Bayer Aktiengesellschaft since March 1, 2018. He completed his Master in Business Economics at the Erasmus University in Rotterdam, the Netherlands. Starting in 1994, he acquired his first professional experience at Heineken. He joined Nestle as an international marketing trainee in 1996, developing his career in sales and marketing management roles in Bangladesh and Indonesia and at the company's global headquarters in Switzerland. He then took up general management roles of increasing importance in the Philippines and, from 2007 to 2013, in the Greater China Region with the aim of developing Nestle's position in this key market. In 2013, Mr. Schipper moved back to Switzerland to lead the global Infant Nutrition Division, a business with both consumer and medical characteristics. He was appointed to the Nestle Group Executive Board in October 2014.

Paul Achleitner

Dr. Paul Achleitner has been Independent Member of the Supervisory Board at Bayer Aktiengesellschaft since April 26, 2002. In addition, he acts as Member of the Company's Presidial and Mediation Committee as well as the Nomination Committee and the Human Resources Committee. Until February 7, 2008 Dr. Achleitner was Chairman of the Supervisory Board of Allianz Elementar Lebensversicherungs-AG and Allianz Elementar Versicherungs-AG, and Vice Chairman of the Supervisory Board of Allianz Investment Bank. He was Member of the Supervisory Board of Allianz Lebensversicherungs-AG until May 7, 2008. Until the end of June 2010 he served on the Supervisory Board of Allianz Deutschland AG. In addition, Dr. Achleitner has been Chairman of the Supervisory Board of Deutsche Bank AG and Member of the Supervisory Board of Daimler AG. He holds a degree from Harvard University and earned a Doctorate in Philosophy degree from Universitaet St. Gallen.

Simone Bagel-Trah

Dr. Simone Bagel-Trah has been Independent Member of the Supervisory Board at Bayer Aktiengesellschaft since April, 2014. She is Independent consultant; project management for the Association of Applied Microbiology; coordination of industrial projects for the Pharmaceutical Microbiology department of the University of Bonn. Since 2000 she has been Founding Partner and Director of Antiinfectives Intelligence Gesellschaft für klinisch-mikrobiologische Forschung und Kommunikation mbH. She is Chairwoman of the Supervisory Board of Henkel AG & Co. KGaA and Henkel Management AG and Shareholders‘ Committee of Henkel AG & Co. KGaA and Member of the Supervisory Board of Heraeus Holding GmbH.

Norbert Bischofberger

Dr. Norbert W. Bischofberger has been Independent Member of the Supervisory Board at Bayer Aktiengesellschaft from April 2017. He is Member of the Innovation Committee at the Company. He is President and Chief Executive Officer at Kronos Bio, Inc. and has served on the Board of Directors of InCarda Therapeutics, Inc. and Kronos Bio, Inc.

Thomas Ebeling

Mr. Thomas Ebeling has been Independent Member of the Supervisory Board of Bayer Aktiengesellschaft since April 27, 2012. He was Chief Executive Officer of ProSiebenSat.1 Media SE. He has been on the Supervisory Board of Apleona GmbH (Chairman), GfK SE and ClearVAT AG.

Thomas Elsner

Dr. Thomas Elsner has been Independent Member of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since April 2017. He is Member of the Audit Committee at the Company. He is Chairman of the Bayer Group Managerial Employees’ Committee and Chairman of the Managerial Employees’ Committee of Bayer AG, Leverkusen

Johanna Faber

Ms. Johanna W. (Hanneke) Faber has been Independent Member of the Supervisory Board of Bayer Aktiengesellschaft since April 30, 2016. Since 2018 she has been President Europe at Unilever N.V./plc. She was Chief E-Commerce and Innovation Officer and Member of the Executive Committee at Koninklijke Ahold Delhaize N.V. from 2016 to 2018. From 2013 to 2016 she was Chief Commercial Officer and Member of the Executive Committee of Koninklijke Ahold N.V., Netherlands, responsible for E-Commerce, Digital, Innovation and Customer Branding / Loyalty. From 2009 to 2013 she served as Vice President & General Manager, Global Pantene, Head & Shoulders & Herbal Essences at Procter & Gamble, the United States, and from 2005 to 2009 she was Vice President & General Manager, Beauty Care Europe & Global Distributors at Procter & Gamble, Switzerland. She joined Procter & Gamble in 1992 in Netherlands and later held various positions, including Brand Manager, Beauty, Hair, Health & Feminine Care at Procter & Gamble, Greece and Marketing Director, Hair Care Europe at Procter & Gamble, Switzerland. In 1990 she obtained Bachelor of Journalism from University of Houston and in 1992 Master of Business Administration from University of Houston.

Colleen Goggins

Ms. Colleen A. Goggins has been Independent Member of the Supervisory Board at Bayer Aktiengesellschaft since April 2017. She is Member of the Board of Directors of The Toronto-Dominion Bank, IQVIA Holdings Inc. and SIG Combibloc Services AG.

Heike Hausfeld

Ms. Heike Hausfeld has been Independent Member of the Supervisory Board, Employee Representative at Bayer Aktiengesellschaft since April 2017. She is Member of the Human Resources Committee at the Company. She is Chairwoman of the Works Council of the Leverkusen site. She is also vice Chairwoman of the Supervisory Board at Bayer Business Services GmbH.

Reiner Hoffmann

Mr. Reiner Hoffmann has served as Independent Member of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since October 11, 2006. He has been Chairman of the German Trade Union Confederation since 2014. Prior to that, he was North Rhine District Secretary of the German Mining, Chemical and Energy Industrial Union, Duesseldorf, among others.

Frank Loellgen

Mr. Frank Loellgen has been Independent Member of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since November 2015. He is Member of the Audit Committee at the Company. He is North Rhine District Secretary of the German Mining, Chemical and Energy Industrial Union and has been on the Supervisory Board of Evonik Industries AG and IRR – Innovationsregion Rheinisches Revier GmbH.

Wolfgang Plischke

Prof. Dr. Wolfgang Plischke has been Independent Member of the Supervisory Board of Bayer Aktiengesellschaft since April 30, 2016. He is Member of the Audit Committee and Chairman of the Innovation Committee at the Company. He was Member of the Management Board, responsible for Innovation, Technology and Environment at the Company from March 1, 2006 to 2014. From July 1, 2002 until his appointment to the Bayer AG Board, he was a Member of the Bayer HealthCare Executive Committee and head of the Pharmaceuticals Division. In 1988, he was placed in charge of marketing in the Pharmaceuticals Business Group in Germany and in 1991 he was appointed head of International Strategic Marketing. In 1995, he became President of Bayer Yakuhin Ltd., Japan, with responsibility for Pharmaceuticals and Consumer Care. In 2000, he took over as head of the Pharmaceuticals Business Group in North America. He joined Bayer in 1980. He has been Member of the Board of Walter-Siegenthaler-Gesellschaft fuer Fortschritte in der Inneren Medizin e. V., Member of the Board of Robert-Koch-Stiftung e. V., Honorary Professor of Business Chemistry at Ludwig Maximilian University of Munich, Member of the University Council of the University of Hohenheim, Chairman of the Supervisory Board of Evotec AG and Member of the Senate of Hermann von Helmholtz-Gemeinschaft Deutscher Forschungszentren e. V., among others. He studied Biology at Universitaet Hohenheim, where in 1979 he obtained doctorate degree.

Petra Reinbold-Knape

Ms. Petra Reinbold-Knape has been Independent Member of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since April 27, 2012. She is Member of the Presidial Committee/Mediation Committee and the Innovation Committee at the Company. She is Member of the Executive Committee of the German Mining, Chemical and Energy Industrial Union, Vice Chairwoman of the Supervisory Board of Lausitz Energie Kraftwerk AG and Lausitz Energie Bergbau AG. She has also been on the Board of DGB Rechtsschutz GmbH.

Detlef Rennings

Mr. Detlef Rennings has been Independent Member of the Supervisory Board, Employee Representative at Bayer Aktiengesellschaft since June 2017. He is Chairman of the Central Works Council of CURRENTA and Chairman of the Works Council of CURRENTA of the Uerdingen site. Moreover, he is Member of the Supervisory Board of Currenta Geschaeftsfuehrungs-GmbH.

Sabine Schaab

Ms. Sabine Schaab has been Independent Member of the Supervisory Board, Employee Representative at Bayer Aktiengesellschaft since October 2017. She is Member of the Innovation Committee at the Company. She is Vice Chairwoman of the Works Council of the Elberfeld site.

Michael Schmidt-Kiessling

Mr. Michael Schmidt-Kiessling has been Independent Member of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since April 27, 2012. He is Chairman of the Works Council of the Elberfeld site.

Andre van Broich

Mr. Andre van Broich has been Independent Member of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since April 27, 2012. He is Member of the Innovation Committee and the Human Resources Committee at the Company. He also acts as Chairman of the Bayer Group Works Council and Chairman of the Works Council of the Dormagen site.

Otmar Wiestler

Prof. Dr. Otmar D. Wiestler has served as Independent Member of the Supervisory Board of Bayer Aktiengesellschaft since October 2014. He is Member of the Innovation Committee at the Company. Since 2015 he has been President of the Helmholtz Association of German Research Centers. In the past, he served as Chairman and Scientific Member of the Management Board of German Cancer Research Center, Vice President for health on executive committee of the Helmholtz Association, Medical Director of LIFE & BRAIN GmbH, Chairman of the BONFOR research committee, Head of German Brain Tumor Reference Center and Professor of Neuropathology at the University of Bonn, among others. In 1984 he obtained Doctoral degree (M.D.) from Universitat Freiburg.

Norbert Winkeljohann

Prof. Dr. Norbert Winkeljohann has been Independent Member of the Supervisory Board of Bayer Aktiengesellschaft since May 25, 2018. He is Chairman of the Audit Committee at the Company. Till June 2018 he was Chairman of the Management Board of PricewaterhouseCoopers GmbH Wirtschaftspruefungsgesellschaft (formerly Chairman of the Management Board of PricewaterhouseCoopers Aktiengesell­schaft Wirtschafts­prüfungsgesellschaft), Chairman of the Board of Management of Pricewaterhouse­Coopers Europe SE, Member of the Network Leadership Team of Pricewaterhouse­Coopers International Limited. Since July 2018 he has been Independent management consultant. He has been on the Supervisory Board of Deutsche Bank Aktiengesellschaft, Georgsmarienhütte Holding GmbH, heristo aktiengesellschaft (Chairman) and Sievert AG (Chairman).

Juergen Beunink